Shots:
- Merck & Moderna have reported the P-III (INTerpath-001) trial data assessing adj. intismeran autogene (1mg, Q3W for 9 doses) + Keytruda (400mg, Q6W up to 9 cycles) vs Keytruda alone in 1,137 pts with high-risk (stage IIB-IV) resected cutaneous melanoma
- Intismeran plus Keytruda as adj. therapy showed improvements in RFS (1EP) and DMFS (2EP) in pts without prior systemic therapy, while the study continues to assess key 2EPs, incl. OS. Data to be presented at an upcoming conference
- INTerpath program incl. 9 P-II & P-III trials across melanoma, NSCLC, bladder cancer & renal cell carcinoma, alongside P-IIb (KEYNOTE-942) trial in adj. melanoma & a P-I study in adj. PDAC, perioperative gastric carcinoma & perioperative NSCLC
Ref: Businesswire | Image: MSD & Moderna | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
